<div id="readability-page-1"><p>Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) has been given a consensus rating of &#34;Buy&#34; by the six analysts that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $61.80.</p><div><p><span></span><span>Get <strong>Tourmaline Bio</strong> alerts:</span></p></div><ul><li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li></ul><p>Separately, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $48.00 price objective on shares of Tourmaline Bio in a research report on Monday, August 12th.</p><p><b>Check Out Our Latest Stock Analysis on Tourmaline Bio</b></p><h2>Insider Buying and Selling</h2><p>In related news, CEO Sandeep Chidambar Kulkarni bought 5,221 shares of the firm's stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.79 per share, for a total transaction of $71,997.59. Following the purchase, the chief executive officer now owns 5,221 shares in the company, valued at $71,997.59. The acquisition was disclosed in a filing with the SEC, which is available through this link. 11.02% of the stock is owned by company insiders. </p><h2>Hedge Funds Weigh In On Tourmaline Bio</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in Tourmaline Bio in the 1st quarter worth $31,000. Quest Partners LLC grew its holdings in Tourmaline Bio by 134.0% in the second quarter. Quest Partners LLC now owns 3,822 shares of the company's stock worth $49,000 after purchasing an additional 2,189 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Tourmaline Bio by 109.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 4,939 shares of the company's stock valued at $113,000 after buying an additional 2,582 shares during the last quarter. Denali Advisors LLC acquired a new position in Tourmaline Bio during the first quarter valued at $128,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Tourmaline Bio in the first quarter worth about $266,000. 91.89% of the stock is owned by institutional investors. </p><h2>Tourmaline Bio Trading Up 8.2 %</h2><p>Shares of NASDAQ TRML opened at $19.27 on Friday. Tourmaline Bio has a 1-year low of $9.18 and a 1-year high of $48.31. The stock has a fifty day simple moving average of $15.62 and a two-hundred day simple moving average of $19.04. The firm has a market cap of $494.08 million, a price-to-earnings ratio of -2.96 and a beta of 2.31. </p><p>Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.04. Analysts forecast that Tourmaline Bio will post -3.12 EPS for the current year. </p><h2>Tourmaline Bio Company Profile</h2> (Get Free Report<p>Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Tourmaline Bio</li><li>5 Top Rated Dividend Stocks to Consider</li><li>Can Celsius Stock Rebound? Analysts See 74% Upside Potential</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>Kroger Stock is a Win-Win for Buy-and-Hold Investors</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>MarketBeat Week in Review – 9/9 - 9/13</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJNTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJNTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ The #1 Altcoin for September 2024 <span><span>(From Crypto 101 Media)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTQ1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NTQ1"/></p><h2>Should you invest $1,000 in Tourmaline Bio right now?</h2><p>Before you consider Tourmaline Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.</p><p>While Tourmaline Bio currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

TRML

<p>Tourmaline Bio, Inc. (NASDAQ:TRML) has received a consensus "Buy" rating from six analysts, with an average price target of $0.80. CEO Sandeep Chidambar Kulkarni recently purchased 5,221 shares at $0.79 each. Institutional investors hold 91.89% of the stock. The stock has risen 8.2% recently, trading at $0.27, with a 1-year range of $0.18 to $0.31. Tourmaline Bio focuses on developing treatments for immune and inflammatory diseases, including its monoclonal antibody TOUR006.</p>

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Analysts